Total revenue expected to be in the range of $145,000,000 to $160,000,000 as compared to previous guidance of $140,000,000 to 160,000,000 dollars XPOVIO net U. S. Product revenue expected to be in the range of $105,000,000 to $120,000,000 as compared to the previous guidance of $100,000,000 to 120,000,000 dollars We are also lowering our expense guidance for the full year of 2024 as follows. R and D and SG and A expenses expected to be in the range of $250,000,000 to $265,000,000 which includes approximately $20,000,000 of estimated non cash stock based compensation expense as compared to previous guidance of $260,000,000 to $280,000,000 And finally, we expect our existing cash, cash equivalents and investments as well as the revenue we expect to generate from exfolvio net product sales and other license revenues will be sufficient to fund our planned operations into Q1 2026. Note that our cash runway does not include paying off the remaining 2025 convertible notes in our $25,000,000 minimum liquidity covenant under the new term loan.